The University of Chicago Header Logo

Noura Choudhury

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Noura Choudhury is a highly skilled and compassionate medical oncologist dedicated to providing exceptional care to patients with thoracic and head and neck malignancies. Dr. Choudhury is also a clinical and translational investigator, with a particular focus in small cell lung cancer. Her expertise is grounded in years of dedicated experience, which allows her to provide personalized care that addresses each patient’s unique needs.

    Using a patient-centered approach to care, Dr. Choudhury ensures that each treatment plan is tailored to her patients’ specific condition, symptoms, lifestyle and healthcare goals. By integrating the latest advancements in cancer care, she strives to enhance the overall well-being of her patients. She has expertise in standard of care treatments such as chemotherapy, immunotherapy and targeted therapies, as well as novel therapeutics such as bispecific T cell engagers, antibody drug conjugates and bispecific antibodies.

    In additional to her clinical work, Dr. Choudhury actively develops clinical trials, contributing to the advancement of cancer treatment. She is national Principal Investigator of an investigator-initiated National Cancer Institute (NCI) phase I/II study in small cell lung cancer, as well as the principal investigator of multiple phase I clinical trials, including first-in-human studies of novel therapeutics. She is a translational physician scientist who strives to bring discoveries in the laboratory to patients in the clinic. Her involvement in leading-edge research allows her to offer her patients access to new therapies and innovative treatments, improving their outcomes and quality of life. Her work also focuses on identifying mechanisms of response and resistance to novel treatment strategies. She is an author on numerous publications, with her work has been published in The Lancet, Clinical Cancer Research, Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, among others.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Repetto M, Richards AL, Chen MF, Selenica P, Suman S, Zhu Y, Wilhelm C, Price A, Yang SR, Wahl J, Hornby Z, Krein P, Hassig C, Chang J, Brannon R, Rosen E, Brown DN, Reis-Filho JS, Raj N, Rudin CM, Kris MG, Ventura A, Berger M, Weigelt B, Drilon A, Choudhury NJ, Donoghue MTA. The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors. Clin Cancer Res. 2026 Sep 15; 32(18):4124-4135. PMID: 42340371.
      Citations:    Fields:    
    2. Sindhwani S, Thomas M, Gehlaut K, Kaur H, Haque W, Juloori A, Choudhury NJ. Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. Drugs. 2026 Sep; 86(9):1513-1533. PMID: 42568026; PMCID: PMC13529872.
      Citations:    Fields:    
    3. Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, Dowlati A, Morgensztern D, Papadopoulos KP, Choudhury NJ, Vieito M, Bar J, Kim JH, Akerley W, Kim TM, Kim YC, Paz-Ares L, Ahn MJ, Yokouchi H, Meiman D, Munasinghe W, Ogunyankin O, Jahchan N, Wang S, Ferlini C, Robinson RR, Kohlhapp FJ, Palenski T, Rivell G, Hingorani P, Chandana S. Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. 2026 Aug; 32(8):3093. PMID: 42374088; PMCID: PMC13472941.
      Citations:    Fields:    
    4. Choudhury NJ, Gezelius E, Arfe A, Baine M, Falcon CJ, Yu H, Rekhtman N, Rudin CM. Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma. J Thorac Oncol. 2026 Jun 24; 104061. PMID: 42341877; PMCID: PMC13383669.
      Citations:    Fields:    
    5. Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, Dowlati A, Morgensztern D, Papadopoulos KP, Choudhury NJ, Vieito M, Bar J, Kim JH, Akerley W, Kim TM, Kim YC, Paz-Ares L, Ahn MJ, Yokouchi H, Meiman D, Munasinghe W, Ogunyankin O, Jahchan N, Wang S, Ferlini C, Robinson RR, Kohlhapp FJ, Palenski T, Rivell G, Hingorani P, Chandana S. SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. 2026 Aug; 32(8):2898-2908. PMID: 42225988; PMCID: PMC13472869.
      Citations:    Fields:    
    6. Ganti AKP, Loo BW, Badiyan S, Bassetti M, Bestvina C, Chiang A, Choudhury N, D'Avella CA, Daly M, Dowlati A, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Khalil M, Lee R, Malhotra J, Merritt RE, Mohindra N, Molina JR, Moran C, Mulvey C, Osmundson EC, Patel S, Patil T, Pokharel S, Puri S, Qin A, Sands J, Shields M, Tailor TD, Waqar SN, Cassara CJ, Ramakrishnan S. NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026. J Natl Compr Canc Netw. 2026 01; 24(1). PMID: 41671459.
      Citations:    Fields:    Translation:Humans
    7. Pietroluongo E, Bestvina CM, Brattin R, De Placido P, Di Lello A, Haque W, Esposito A, Bianco R, Choudhury N, Garassino MC. Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches. JTO Clin Res Rep. 2026 Feb; 7(2):100935. PMID: 41584722; PMCID: PMC12828808.
      Citations:    
    8. Ross JS, Thummalapalli R, Febres-Aldana CA, Muldoon D, Falcon C, Pupo A, Choudhury NJ, Harada G, Yang SR, Eckert S, Bodd FM, Sauter JL, Bandlamudi C, Berger M, Jeng MY, Offin M, Drilon A, Kris MG, Awad MM, Yu H, Riely GJ, Ladanyi M, Arbour KC. Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC. J Thorac Oncol. 2026 03; 21(3):103520. PMID: 41260457.
      Citations:    Fields:    Translation:Humans
    9. Choudhury NJ, Kothari A, Bestvina CM, Issaeva N. Bridging EGFR/TGF-ß Signaling to Bypass Resistance to Immune Checkpoint Blockade. Clin Cancer Res. 2025 Nov 14; 31(22):4617-4619. PMID: 40986506.
      Citations:    Fields:    Translation:HumansCells
    10. Chen MF, Lee JJ, Choudhury NJ, Hui AB, Jeng MY, Zheng J, Aly RG, Sielski N, Ahn L, Pupo A, Nesselbush MC, Jabara I, Wilcox JA, Santomasso BD, Lin AL, Schaff L, Chaft JE, Riely GJ, Kris MG, Arfe A, Yang SR, Young RJ, Diehn M, Boire A, Yu HA. Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 03; 21(3):103505. PMID: 41139066; PMCID: PMC13564235.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    11. Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z, Qian X, Brentnall M, Heeke S, Poi M, Wu S, Rudin CM. Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes. Clin Cancer Res. 2025 Aug 14; 31(16):3476-3482. PMID: 40553459; PMCID: PMC12351277.
      Citations: 5     Fields:    Translation:Humans
    12. Rosenberg AJ, Izumchenko E, Juloori A, Katipally R, Cursio J, Choudhury N, Gooi Z, Blair E, Chin J, Hasina R, Vannier A, Starus A, Jones FS, Gramiccioni EL, Miao Y, Haraf DJ, Vokes EE, Pearson AT, Agrawal N, Rosenberg AJ, Izumchenko E, Juloori A, Katipally R, Cursio J, Choudhury N, Gooi Z, Blair E, Chin J, Hasina R, Vannier A, Starus A, Jones FS, Gramiccioni EL, Miao Y, Haraf DJ, Vokes EE, Pearson AT, Agrawal N. Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159. PMID: 40423530; PMCID: PMC12332768.
      Citations: 2     Fields:    Translation:HumansCells
    13. Choudhury NJ, Garassino MC. Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer. Lancet. 2025 Jun 14; 405(10495):2104-2106. PMID: 40516996.
      Citations:    Fields:    
    14. Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK. Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer. 2025 Feb 01; 131(3):e35738. PMID: 39876075; PMCID: PMC11775405.
      Citations: 10     Fields:    Translation:HumansCells
    15. Rekhtman N, Tischfield SE, Febres-Aldana CA, Lee JJ, Chang JC, Herzberg BO, Selenica P, Woo HJ, Vanderbilt CM, Yang SR, Xu F, Bowman AS, da Silva EM, Noronha AM, Mandelker DL, Mehine M, Mukherjee S, Blanco-Heredia J, Orgera JJ, Nanjangud GJ, Baine MK, Aly RG, Sauter JL, Travis WD, Savari O, Moreira AL, Falcon CJ, Bodd FM, Wilson CE, Sienty JV, Manoj P, Sridhar H, Wang L, Choudhury NJ, Offin M, Yu HA, Quintanal-Villalonga A, Berger MF, Ladanyi M, Donoghue MTA, Reis-Filho JS, Rudin CM. Chromothripsis-Mediated Small Cell Lung Carcinoma. Cancer Discov. 2025 Jan 13; 15(1):83-104. PMID: 39185963; PMCID: PMC11726019.
      Citations: 16     Fields:    Translation:Humans
    16. Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5042-5052. PMID: 39287821; PMCID: PMC11565168.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    17. Choudhury NJ, Lai WV, Makhnin A, Heller G, Eng J, Li B, Preeshagul I, Santini FC, Offin M, Ng K, Paik P, Larsen C, Ginsberg MS, Lau Y, Zhang X, Baine MK, Rekhtman N, Rudin CM. A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. Clin Cancer Res. 2024 Sep 03; 30(17):3697-3703. PMID: 38940666; PMCID: PMC11371507.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    18. Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. Lancet Oncol. 2024 08; 25(8):1015-1024. PMID: 38950555; PMCID: PMC11656522.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    19. Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib. JCO Precis Oncol. 2024 06; 8:e2300721. PMID: 38848521; PMCID: PMC11545664.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate. medRxiv. 2024 Jan 11. PMID: 38260492; PMCID: PMC10802659.
      Citations:    
    21. Choudhury NJ, Lavery JA, Brown S, de Bruijn I, Jee J, Tran TN, Rizvi H, Arbour KC, Whiting K, Shen R, Hellmann M, Bedard PL, Yu C, Leighl N, LeNoue-Newton M, Micheel C, Warner JL, Ginsberg MS, Plodkowski A, Girshman J, Sawan P, Pillai S, Sweeney SM, Kehl KL, Panageas KS, Schultz N, Schrag D, Riely GJ, AACR GENIE BPC Core Team. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 09 01; 29(17):3418-3428. PMID: 37223888; PMCID: PMC10472103.
      Citations: 18     Fields:    Translation:Humans
    22. Thummalapalli R, Choudhury NJ, Ehrich F, Beardslee T, Brazel D, Zhang SS, Merchant S, Chen MF, Heller G, Ramalingam SS, Ou SI, Mileham KF, Riely GJ. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report. JTO Clin Res Rep. 2023 Aug; 4(8):100546. PMID: 37644967; PMCID: PMC10460990.
      Citations: 4     
    23. Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, Geese WJ, Hellmann MD, Forslund A. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. J Thorac Oncol. 2023 09; 18(9):1222-1232. PMID: 37210008; PMCID: PMC10524620.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    24. Choudhury NJ, Marra A, Sui JSY, Flynn J, Yang SR, Falcon CJ, Selenica P, Schoenfeld AJ, Rekhtman N, Gomez D, Berger MF, Ladanyi M, Arcila M, Rudin CM, Riely GJ, Kris MG, Heller G, Reis-Filho JS, Yu HA. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. J Thorac Oncol. 2023 04; 18(4):463-475. PMID: 36494075; PMCID: PMC10249779.
      Citations: 48     Fields:    Translation:Humans
    25. Solomon JP, Yang SR, Choudhury NJ, Ptashkin RN, Eslamdoost N, Falcon CJ, Martin A, Plodkowski A, Wilhelm C, Shen R, Ladanyi M, Berger M, Zhang Y, Drilon A, Arcila ME. Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors. Clin Cancer Res. 2022 11 01; 28(21):4649-4659. PMID: 36044468; PMCID: PMC9633455.
      Citations: 7     Fields:    Translation:Humans
    26. Hubbeling H, Choudhury N, Flynn J, Zhang Z, Falcon C, Rusch VW, Park BJ, Ziv E, Shaverdian N, Gelblum DY, Shepherd AF, Simone CB, Wu AJ, Gomez DR, Drilon A, Rimner A. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers. JCO Precis Oncol. 2022 Oct; 6:e2200024. PMID: 36201714; PMCID: PMC9848570.
      Citations: 7     Fields:    Translation:Humans
    27. Choudhury NJ, Riely GJ. Serplulimab With Chemotherapy in Extensive-Stage SCLC. JAMA. 2022 09 27; 328(12):1205-1207. PMID: 36166047.
      Citations: 3     Fields:    Translation:Humans
    28. Choudhury NJ, Schneider JL, Patil T, Zhu VW, Goldman DA, Yang SR, Falcon CJ, Do A, Nie Y, Plodkowski AJ, Chaft JE, Digumarthy SR, Rekhtman N, Arcila ME, Iasonos A, Ou SI, Lin JJ, Drilon A. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clin Res Rep. 2021 Jul; 2(7):100187. PMID: 34590036; PMCID: PMC8474494.
      Citations: 28     
    29. Choudhury NJ, Riely GJ, Sabbatini PJ, Hellmann MD. Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research. Cancer Cell. 2021 07 12; 39(7):897-899. PMID: 34004186; PMCID: PMC8103143.
      Citations: 1     Fields:    Translation:Humans
    30. Choudhury NJ, Makhnin A, Tobi YY, Daly RM, Preeshagul IR, Iqbal AN, Ahn LS, Hayes SA, Heller G, Kris MG, Riely GJ, Yu HA. Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precis Oncol. 2021; 5. PMID: 34250398; PMCID: PMC8232442.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    31. Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 05 15; 27(10):2899-2909. PMID: 33685866; PMCID: PMC8127383.
      Citations: 81     Fields:    Translation:HumansCells
    32. Choudhury NJ, Schoenfeld AJ, Flynn J, Falcon CJ, Rizvi H, Rudin CM, Kris MG, Arcila ME, Heller G, Yu HA, Ladanyi M, Riely GJ. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clin Cancer Res. 2021 05 15; 27(10):2920-2927. PMID: 33685865; PMCID: PMC8127357.
      Citations: 35     Fields:    Translation:Humans
    33. Choudhury NJ, Drilon A. Decade in review: a new era for RET-rearranged lung cancers. Transl Lung Cancer Res. 2020 Dec; 9(6):2571-2580. PMID: 33489819; PMCID: PMC7815364.
      Citations: 24     
    34. Choudhury NJ, Yang SR, Arcila M, Mohanty AS, Boire A, Drilon A. Genomic Characterization of a RET Inhibitor-Resistant RET Fusion-Positive Lung Cancer by CSF Cell-Free DNA Hybrid Capture-Based Sequencing. JCO Precis Oncol. 2020; 4. PMID: 33381675; PMCID: PMC7768332.
      Citations:    Fields:    
    35. Choudhury NJ, Young RJ, Sellitti M, Miller A, Drilon A. Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression. JCO Precis Oncol. 2020; 4. PMID: 33283131; PMCID: PMC7713518.
      Citations: 8     Fields:    
    36. Choudhury N, Shoushtari A. Training Oncologists in the Time of COVID-19. Oncologist. 2020 07; 25(7):546-547. PMID: 32484588; PMCID: PMC7300728.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
    37. Choudhury NJ, Eghtesad M, Kadri S, Cursio J, Ritterhouse L, Segal J, Husain A, Patel JD. Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center. Oncotarget. 2019 Oct 08; 10(56):5817-5823. PMID: 31645901; PMCID: PMC6791384.
      Citations: 14     Fields:    
    38. Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W. WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018; 7:1. PMID: 29344432; PMCID: PMC5765712.
      Citations: 13     
    39. Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, Karrison T, Stadler WM, Nakamura Y, O'Donnell PH. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71. PMID: 27044931; PMCID: PMC5569685.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    40. Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15. PMID: 26678880; PMCID: PMC4768396.
      Citations: 18     Fields:    Translation:Humans
    41. Choudhury NJ, Kiyotani K, Yap KL, Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y, O'Donnell PH. Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. Eur Urol Focus. 2016 Oct; 2(4):445-452. PMID: 28723478.
      Citations: 55     Fields:    
    42. Xu J, Prosperi JR, Choudhury N, Olopade OI, Goss KH. ß-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One. 2015; 10(2):e0117097. PMID: 25658419; PMCID: PMC4319896.
      Citations: 115     Fields:    Translation:HumansAnimalsCells
    43. Choudhury N, Khanwalkar A, Kraninger J, Vohra A, Jones K, Reddy S. Peer mentorship in student-run free clinics: the impact on preclinical education. Fam Med. 2014 Mar; 46(3):204-8. PMID: 24652639.
      Citations: 7     Fields:    Translation:Humans
    Choudhury's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (151)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _